KONEXBiotech & Pharma215570

Cronex

₩600 0.00%2026-10-02 close

Market Cap

₩4B

Turnover

₩11,319

Volume

21 shares

Shares out.

6.7M

PER

—

PBR

—

EPS

—

Dividend Yield

0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Unique Mini-Pig Bioplatform — Monetization Still Pending

Cronex holds a uniquely defensible position in SPF mini-pig production and CRISPR-based xenotransplantation R&D in Korea, yet persistent operating losses and near-zero market liquidity on KONEX make valuation assessment highly difficult.

1
Korea's only ISO-certified large-scale animal production facility for xenotransplantation — differentiated vs. Optipharm and MGenPlus
2
First in Korea (second globally) to mass-produce mini-pigs with three immune-rejection genes simultaneously removed via CRISPR-Cas12
3
Jeju Genetic Resources Research Center (9,600㎡) targeted for completion end-2025 and commercial operation from 2026 — key inflection point
4
FY2023 standalone revenue grew 4% YoY but operating loss widened 15.1% — profitability not yet achieved
5
Reference-date trading value of just KRW 39,302; 52-week range of KRW 408–2,300 — extreme illiquidity combined with high volatility

Business structure

Cronex was founded in May 2012 and listed on KONEX in 2015 as a small-cap biotech. Its business is structured around three pillars: (1) non-clinical CRO services, (2) biological specimen supply (SPF mini-pig breeding and sales), and (3) bio-materials and xenotransplantation R&D.

According to a 2020 Ebest Investment Securities research note, the non-clinical CRO segment accounts for the largest share of revenue, while the biological specimen segment contributed roughly 40%.

The CRO business outsources efficacy and safety testing using animal models for drug and medical device prototypes, serving clients such as LG Electronics, Classys, Osstem Implant, Seoul National University, and Yonsei University's Dental College.

On the production side, the company operates a Ministry of Food and Drug Safety-designated Good Laboratory Practice (GLP) facility in Cheongju, Chungbuk, certified in July 2019, and opened an additional non-clinical testing center in Suwon in 2022 covering cosmetics, pharmaceuticals, and health functional foods.

Key competitors include Optipharm (153710) and MGenPlus (032790), but Cronex is assessed as the only company in Korea with an ISO-certified large-scale production facility for bio-materials and xenotransplantation-grade animals.

The Jeju native black pig, the company's core biological asset, is a domestic endemic breed free from the Nagoya Protocol's access and benefit-sharing requirements, providing both pricing leverage and supply-chain independence.

In xenotransplantation, the company employs CRISPR-Cas12 gene editing — licensed from the Broad Institute — to simultaneously remove three immune-rejection genes (α-GaL, CMAH, β4GALNT2) from mini-pigs, achieving mass production that is a first in Korea and second in the world.

Jeju province has granted the company a 20-year free land lease on a 9,600㎡ site and signed an exclusive MOU with Jeju National University and the Jeju Livestock Promotion Institute, securing a strong regional partnership framework.

Recent trends

Based on FnGuide's compilation of disclosed financial data, Cronex's FY2023 standalone revenue grew 4% year-on-year, while the operating loss widened by 15.1%; however, the net loss narrowed by 52.8%, indicating a partial improvement in bottom-line profitability.

Since its KONEX listing in 2015, the company had reported a compound annual revenue growth rate of approximately 36%, reaching roughly KRW 3.8 billion in FY2019, but it has yet to achieve operating breakeven.

In 2023, the company completed a patent application for an albino pig model derived from Jeju native pigs and announced it was preparing additional patent filings related to SPF mini-pig production methods.

In 2025, Cronex was selected as an outstanding company under the Korea Institute for Advancement of Technology's ATC+ program, and KRX issued a formal technical analysis report (Tech 2025-130) on the company in September 2025, validating its technological capabilities.

As of the reference date (June 7, 2026), the share price stands at KRW 890, while the 52-week range per Investing.com data (as of May 15, 2026) spans from KRW 408 to KRW 2,300 — reflecting extreme price volatility. The reference-date trading value of just KRW 39,302 indicates near-zero market liquidity.

This is consistent with the broader structural deterioration of the KONEX market: as of November 2025, KONEX's annual average daily trading value had fallen to an all-time low of KRW 1.762 billion.

The company previously raised KRW 2 billion via a convertible bond (conversion price ~KRW 5,500) from AIM Investment in December 2020, and conducted a KRW 5.6 billion third-party allotment capital increase in 2021, underscoring its continued reliance on external capital for facility investment.

Outlook

The most significant near-term catalyst for Cronex is the scheduled completion of the Jeju Genetic Resources Research Center by end-2025 and its commercial operation from 2026.

Once operational, the facility — developed on a 9,600㎡ site leased rent-free from Jeju Province for 20 years — will enable simultaneous housing of 1,400 head and annual production of over 2,000 mini-pigs, providing the foundational infrastructure for entry into the high-value bio-materials market, including high-purity collagen medical devices.

Management has publicly targeted KRW 50 billion in annual non-clinical CRO revenue within three years, implying more than a 13-fold increase over the FY2019 revenue base.

On the KOSDAQ transfer listing front, the company stated plans to select an IPO lead manager by October 2025, with full transfer targeting completion within three years, backed by ongoing improvements to its internal accounting, legal, and quality management systems.

The structural expansion of Korea's non-clinical CRO market — driven by sustained K-bio drug development momentum — underpins medium-term demand growth. In xenotransplantation, the global accumulation of clinical cases and the gradual maturation of the regulatory environment represent a slowly emerging tailwind.

However, the Jeju center startup timeline carries execution risk, bio-material product licensing remains uncertain, and the commercialization timeline for xenotransplantation is inherently long.

Should the KOSDAQ transfer listing succeed, institutional accessibility and market liquidity would improve meaningfully, but the current share price of KRW 890 represents a significant discount to the KRW 5,500 convertible bond conversion price, implying latent dilution pressure.

Bull factors

Domestic Monopoly in Mini-Pig Infrastructure

Cronex operates Korea's only ISO-certified large-scale production facility for bio-material and xenotransplantation-grade animals, a barrier that is structurally difficult for domestic rivals to replicate.

The company's MFDS-designated GLP facility, cleanroom proprietary pathogen verification system, and the emerging Jeju facility create a layered competitive moat.

Under the Nagoya Protocol, which tightens access to foreign genetic resources, the use of Jeju native black pigs — a domestic endemic breed — provides both supply independence and pricing power that foreign-sourced platforms cannot easily match.

The expansion of SPF mini-pig production capacity (over 2,000 head annually post-Jeju launch) directly addresses the supply-deficit conditions in Korea's experimental animal market.

First-Mover Gene-Editing Technology in Xenotransplantation

Cronex successfully mass-produced mini-pigs with three key immune-rejection genes simultaneously removed using Broad Institute's CRISPR-Cas12 technology — a first in Korea and second globally — establishing a credible early-mover advantage in the emerging xenotransplantation supply chain.

This capability is a prerequisite for commercializing next-generation xenotransplantation, and the company's patent portfolio in this area is expanding. With over 20,000 patients in Korea awaiting organ transplants and an aging population structurally driving demand, the long-term market potential is substantial.

The global accumulation of pig-to-human xenotransplantation clinical cases is gradually shaping regulatory frameworks, positioning Cronex's production infrastructure for direct benefit as those frameworks mature.

KOSDAQ Transfer Listing as a Liquidity Catalyst

As reported in July 2025, Cronex is targeting the selection of a KOSDAQ IPO lead manager by end-October 2025, with a full transfer listing expected within three years, backed by ongoing internal accounting, legal, and quality management improvements.

Academic research has documented that KONEX companies transferring to KOSDAQ statistically outperform direct-listing peers in long-term share price performance, suggesting the transfer itself could serve as a re-rating catalyst.

A successful listing would open the company to institutional investor participation and structurally improve liquidity, dissolving the severe illiquidity discount embedded in the current share price.

The Jeju center's commercial launch and the visibility of bio-material product revenue are the key criteria for meeting transfer listing requirements, making the timing and sequencing of these two events strategically interlinked.

Bear factors

Persistent Operating Losses and Ongoing Capital Needs

According to FnGuide's compiled financial data, Cronex's operating loss widened by 15.1% in FY2023, and the company has yet to achieve operating breakeven since its 2015 KONEX listing.

The company has relied on successive external funding rounds — a KRW 2 billion convertible bond and a KRW 5.6 billion capital increase — to fund the Jeju facility, and initial startup costs and R&D expenditures after the center's launch are likely to weigh on near-term profitability.

The convertible bond issued in 2020 carries a conversion price of KRW 5,500, roughly six times the current share price of KRW 890, making conversion unlikely in the near term, but future refinancing rounds carry fresh dilution risk.

The core non-clinical CRO segment also faces intensifying competition from larger pharmaceutical groups and domestic CRO operators, potentially compressing margins over the medium term.

Extreme KONEX Illiquidity

The reference-date trading value of just KRW 39,302 illustrates the near-complete absence of market liquidity. As reported in November 2025, the KONEX market's annual average daily trading value fell to an all-time low of KRW 1.762 billion, and the KONEX total market cap dropped below KRW 3 trillion for the first time.

Institutional investors — including pension funds, insurers, and banks — had zero net purchasing in KONEX throughout 2025, reflecting a structural absence of long-term capital.

In this environment, price discovery is non-functional; the gap between intrinsic value and market price can persist indefinitely, and a meaningful re-rating is effectively impossible without a liquidity event such as a KOSDAQ transfer listing.

Long Commercialization Horizon for Xenotransplantation

The xenotransplantation segment remains in the research and animal-trial stage, requiring several more years before clinical application and commercialization.

The Jeju research center itself suffered a multi-year delay from an originally targeted 2021 completion to an end-2025 revised schedule, which warrants a discount on future project milestones.

Regulatory frameworks for xenotransplantation remain immature globally, and residual technical risks — including pathogen transmission concerns — persist.

The segment is unlikely to generate meaningful cash flow in the near term, and its value will probably remain priced as an option rather than a quantifiable earnings contributor for the foreseeable future.

Risk factors

Macro / Sector Risk

The prolonged high-rate global environment and compressed risk appetite suppress valuation premiums for small-cap KONEX biotech companies. A slowdown in Korea's new drug development cycle would directly dampen non-clinical CRO demand growth.

The government is actively debating a restructuring of the KONEX/KOSDAQ market framework, which could alter transfer listing conditions or procedures in ways that are difficult to predict.

Even after a potential KOSDAQ transfer listing, institutional investor interest may remain limited if broader biotech sector sentiment does not recover.

Execution Risk

Given the Jeju center's track record of multi-year delays, further schedule slippage or cost overruns could significantly strain the company's already thin balance sheet.

The timing of regulatory approval from the MFDS for collagen medical device products and the speed of market penetration are critical to achieving the stated three-year KRW 50 billion revenue target, but licensing risk remains highly uncertain.

In the non-clinical CRO segment, the domestic expansion of larger CRO operators, tighter animal testing regulations, and advances in alternative testing methods (in vitro and computer simulation models) could challenge the long-term viability of the current business model. The risk of key personnel attrition is also non-trivial given the company's small scale.

Financial / Liquidity Risk

The company has sustained its growth investments through repeated external fundraising while remaining in operating loss.

With the current share price of KRW 890 sharply below the KRW 5,500 convertible bond conversion price from 2020, any future refinancing via new convertible bonds or rights issues is likely to be priced on terms unfavorable to existing shareholders.

The extreme illiquidity on KONEX makes equity market funding practically inaccessible, and without institutional investor participation, the range of viable capital-raising options is limited.

Should the KOSDAQ transfer listing fail to proceed on schedule, the path to financial restructuring and balance sheet improvement becomes materially more complex.

Overall view

Cronex possesses a structurally defensible niche position built on Korea's only ISO-certified SPF mini-pig production infrastructure, world-class CRISPR-based xenotransplantation gene-editing capability, and an exclusive regional partnership framework with Jeju Province.

If the Jeju Genetic Resources Research Center is completed as planned by end-2025 and commences operation in 2026, it would represent a meaningful inflection point, simultaneously unlocking the bio-materials segment and expanding CRO production capacity.

However, the most recently confirmed financial data through FY2023 still shows a widening operating loss, and the reference-date trading value of KRW 39,302 illustrates that investor access is effectively blocked.

Years of incremental revenue improvement are required before the KRW 50 billion revenue target is achievable, and monetization of the xenotransplantation segment remains a long-cycle proposition given regulatory and technical uncertainty.

Until the KOSDAQ transfer listing timeline becomes concrete and early Jeju center operating results are confirmed, the current share price appears to reflect more expectation than demonstrated value, warranting a cautious stance.

The three key monitoring points at this stage are: (1) progress on Jeju center operations and bio-material product licensing in 2026; (2) confirmation of a KOSDAQ IPO lead manager appointment and preliminary review filing; and (3) FY2024–2025 revenue growth and operating loss improvement trends.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 10 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.